ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the ARS Pharmaceuticals Conference Call. At this time, all participants are in a listen-only mode. After the company's prepared remarks, we'll open the line for questions. Please be advised today's conference is being recorded. I'll now turn the call over to Justin Chakpa, Chief Business Officer. Please go ahead. Good morning and thank you for joining our second quarter 2025 earnings conference call. This morning, we issued a press release detailing our financial results and commercial highlights. which is available in the investors and media section of our website at ars-pharma.com. With me on the call are Richard Lowenthal, our co-founder, president, and CEO, who will review recent corporate updates and achievements. Eric Perez, our chief commercial officer, will cover our commercial activities and progress. And Kathy Scott, our CFO, who will provide a summary of our financial results and cash positions. Before we begin, please note that today's remarks may contain forward-looking statements. Actual results may differ materially. Please refer to our earnings release and SEC filings for further risk disclosures. With that, I'll turn the call over to Rich. Thank you, Justin. Good morning, everybody, and thank you for joining us to discuss our commercial momentum with NEFI in the second quarter of this year and early weeks of the third quarter. We have long believed that a needle-free, portable, and reliable epinephrine treatment option could transform how patients and providers treat severe allergies. The commercial data we will share today confirm that this vision is becoming a reality. NEFI is gaining traction across prescribers, payers, and patients, which we will talk about during this presentation. Our momentum is reflected in the con...